目的 探究双石通淋胶囊联合罗红霉素治疗IIIA型前列腺炎的临床效果。方法 选取2020年1月—2020年10月在天津市东丽区东丽医院接受治疗的118例IIIA型前列腺炎患者，使用随机数字表的方法分为对照组和治疗组，每组各59例。对照组饭前口服罗红霉素缓释胶囊，1粒/次，1次/d。治疗组在对照组基础上饭前口服双石通淋胶囊，4粒/次，3次/d。两组均连续治疗4周。观察两组的临床疗效，比较两组患者慢性前列腺炎症状指数评分（NIH-CPSI）、炎症指标及前列腺液γ干扰素（IFN-γ）、转化生长因子β1（TGF-β1）水平。结果 治疗后，治疗组患者总有效率为94.9%，显著高于对照组的83.1%（P<0.05）。治疗后，两组患者疼痛或不适评分、排尿症状评分、生活质量评分、NIH-CPSI总评分均显著降低（P<0.05）；治疗后治疗组NIH-CPSI评分显著低于对照组（P<0.05）。治疗后，两组白细胞（WBC）、C反应蛋白（CRP）、白细胞介素-2（IL-2）水平较较治疗前显著降低（P<0.05）；治疗后治疗组炎症指标水平显著低于对照组（P<0.05）。治疗后，两组患者IFN-γ、TGF-β1水平均显著降低（P<0.05）；治疗后，治疗组前列腺液IFN-γ、TGF-β1水平低于对照组（P<0.05）。结论 双石通淋胶囊联合罗红霉素治疗IIIA型前列腺炎具有较好的临床疗效，能够有效改善患者的临床症状，降低炎症反应，且安全性较好，值得临床推广。

Objective To explore the therapeutic effect of Shuangshi Tonglin Capsules combined with roxithromycin in treatment of type IIIA prostatitis. Methods A total of 118 patients with type IIIA prostatitis who were treated in Dongli Hospital of Dongli District in Tianjin from January 2020 to October 2020 were selected and divided into control group and treatment group by random number table method, with 59 cases in each group. Patients in the control group were po administered with Roxithromycin Sustained Release Capsules, 1 grain/time, once daily. Patients in the treatment group were po administered with Shuangshi Tonglin Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the chronic prostatic inflammation index score (NIH-CPSI), inflammatory indicators, prostatic fluid interferon γ (IFN-γ), transforming growth factor β1 (TGF-β1) levels were compared between two groups. Results After treatment, the total effective rate in the treatment group was 94.9%, which is significantly higher than that in the control group (83.1%) (P < 0.05). After treatment, pain or discomfort score, urination symptom score, life quality score and NIH-CPSI total score in treatment group were significantly decreased (P < 0.05). NIH-CPSI score in treatment group was significantly lower than that in control group (P < 0.05). After treatment, the levels of white blood cell (WBC), C-reactive protein (CRP), and interleukin-2 (IL-2) in two groups were significantly decreased (P < 0.05). After treatment, the levels of inflammatory indicators in treatment group were significantly lower than those in control group (P < 0.05). After treatment, the levels of IFN-γ and TGF-β1 in two two groups were significantly decreased (P < 0.05). After treatment, the levels of IFN-γ and TGF-β1 in prostatic fluid in treatment group were lower than those in control group (P < 0.05). Conclusion Clinical study of Shuangshi Tonglin Capsules combined with roxithromycin has good clinical effect in treatment of type IIIA prostatitis, and can effectively improve the clinical symptoms of patients, reduce the inflammatory response with good safety, which is worthy of clinical promotion.

R983

天津市卫生和计划生育委员会科研基金项目（2017KZ059）